NCT04594135View on ClinicalTrials.gov

Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies

PHASE1UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions
T-cell Acute Lymphoblastic LeukemiaT-cell Non-Hodgkin Lymphoma
Interventions
DRUG

anti-CD5 CAR T cells

anti-CD5 CAR T cells transduced with a lentiviral vector to express CD5 chimeric receptor domain on T cells

Trial Locations (1)

Unknown

RECRUITING

Peking University Shenzhen Hospital, Shenzhen

Sponsors
All Listed Sponsors
collaborator

iCAR Bio Therapeutics Ltd.

INDUSTRY

collaborator

Peking University Shenzhen Hospital

OTHER

lead

iCell Gene Therapeutics

INDUSTRY

NCT04594135 - Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies | Biotech Hunter | Biotech Hunter